Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.53 |
| ▸ | USP30 | Q70CQ3 | 9/20 | 0.53 |
| ▸ | HSD11B1 | P28845 | 6/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | PARP1 | P09874 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18632877 | 1.00 | EPHX1 (0.53) | EPHX1USP30HSD11B1CYP2C9HDAC4 | |
| SCHEMBL30505540 | 1.00 | EPHX1 (0.53) | EPHX1USP30HSD11B1CYP2C9HDAC4 | |
| SCHEMBL13636132 | 0.92 | USP30 (0.55) | EPHX1USP30HSD11B1CYP2C9HDAC4 | |
| SCHEMBL25948405 | 0.92 | USP30 (0.55) | EPHX1USP30HSD11B1CYP2C9HDAC4 | |
| SCHEMBL25948398 | 0.92 | USP30 (0.55) | EPHX1USP30HSD11B1CYP2C9HDAC4 | |
| SCHEMBL4206232 | 0.92 | EPHX1 (0.63) | EPHX1HDAC4PARP1 | |
| SCHEMBL25245907 | 0.88 | NR1H2 (0.48) | EPHX1USP30 | |
| SCHEMBL17560314 | 0.87 | EPHX1 (0.55) | EPHX1USP30HSD11B1CYP2C9HDAC4 | |
| SCHEMBL2040388 | 0.87 | EPHX1 (0.55) | EPHX1USP30HSD11B1CYP2C9HDAC4 | |
| SCHEMBL17560313 | 0.87 | EPHX1 (0.55) | EPHX1USP30HSD11B1CYP2C9HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080300232-A1 | N-Piperidine Derivatives as Ccr3 Modulators | ASTRAZENECA AB (SE) | 2008-12-04 | — | — | US | disclosed |
| EP-1730136-A1 | N-PIPERIDINE DERIVATES AS CCR3 MODULATORS | AstraZeneca AB (SE) | 2006-12-13 | — | — | EP | disclosed |
| WO-2005090330-A1 | N-PIPERIDINE DERIVATES AS CCR3 MODULATORS | ASTRAZENECA AB (SE) | 2005-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300232-A1 | N-Piperidine Derivatives as Ccr3 Modulators | CCR3, CCR1, CCR4 | EPHX1 1340/4885USP30 1342/4885HSD11B1 2053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.